AIM2 and neoplasm: Therefore, vaccination with AIM2-deficient DCs improves the efficacy of adoptive T-cell therapy and anti-PD-1 Ab for “cold tumors.” This effect depends on STING activation and IFN-β production, leading to CXCL10-mediated recruitment of T cells into the tumor.